Beneficial Outcome of Losartan Therapy Depends on Type of FBN1 Mutation in Marfan Syndrome
Circulation: Cardiovascular Genetics · 2015-04 · 8 (2) · 383-388
DOI: 10.1161/circgenetics.114.000950 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Circulation: Cardiovascular Genetics, 2015-04. Verfasst von Romy Franken und 14 weiteren Autor:innen. Beteiligte Einrichtung: From the Departments of Cardiology (R.F., A.W.d.H., M.G., B.J.M.M.), Radiology (M.G.), Clinical Epidemiology and Biostatistics (A.H.Z.), and Medical …. Hauptthemen laut MEDLINE: Genes, Dominant, Haploinsufficiency, Marfan Syndrome, Microfilament Proteins. Die Arbeit wurde bisher 165-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Background— It has been shown that losartan reduces aortic dilatation in patients with Marfan syndrome. However, treatment response is highly variable. This study investigates losartan effectiveness in genetically classified subgroups. Methods and Results— In this predefined substudy of COMPARE, Marfan patients were randomized to daily receive losartan 100 mg or no losartan. Aortic root dimensions were measured by MRI at baseline and after 3 years. FBN1 mutations were classified based on fibrillin-1 protein effect into (1) haploinsufficiency, decreased amount of normal fibrillin-1, or (2) dominant negative, normal fibrillin-1 abundance with mutant fibrillin-1 incorporated in the matrix. A pathogenic FBN1 mutation was found in 117 patients, of whom 79 patients were positive for a dominant negative mutation (67.5%) and 38 for a mutation causing haploinsufficiency (32.5%). Baseline characteristics between treatment groups were similar. Overall, losartan significantly reduced aortic root dilatation rate (no losartan, 1.3±1.5 mm/3 years, n=59 versus losartan, 0.8±1.4 mm/3 years, n=58; P =0.009). However, losartan reduced only aortic root dilatation rate in haploinsufficient patients (no losartan, 1.8±1.5 mm/3 years, n=21 versus losartan 0.5±0.8 mm/3 years, n=17; P =0.001) and not in dominant negative patients (no losartan, 1.2±1.7 mm/3 years, n=38 versus losartan 0.8±1.3 mm/3 years, n=41; P =0.197). Conclusions— Marfan patients with haploinsufficient FBN1 mutations seem to be more responsive to losartan therapy for inhibition of aortic root dilatation rate compared with dominant negative patients. Additional treatment strategies are needed in Marfan patients with dominant negative FBN1 mutations. Clinical Trial Registration— http://www.trialregister.nl/trialreg/index.asp ; Unique Identifier: NTR1423.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- From the Departments of Cardiology (R.F., A.W.d.H., M.G., B.J.M.M.), Radiology (M.G.), Clinical Epidemiology and Biostatistics (A.H.Z.), and Medical Biochemistry (V.d.W.), Academic Medical Center Amsterdam, Amsterdam; I…
Zitieren
APA
Franken, R., den Hartog, A. W., Radonic, T., Micha, D., Maugeri, A., van Dijk, F. S., Meijers-Heijboer, H. E., Timmermans, J., Scholte, A. J., van den Berg, M. P., Groenink, M., Mulder, B. J., Zwinderman, A. H., de Waard, V., & Pals, G. (2015). Beneficial Outcome of Losartan Therapy Depends on Type of FBN1 Mutation in Marfan Syndrome. Circulation: Cardiovascular Genetics, 8(2), 383-388. https://doi.org/10.1161/circgenetics.114.000950
Vancouver
Franken R, den Hartog AW, Radonic T, Micha D, Maugeri A, van Dijk FS, et al. Beneficial Outcome of Losartan Therapy Depends on Type of FBN1 Mutation in Marfan Syndrome. Circulation: Cardiovascular Genetics. 2015;8(2):383-388. doi:10.1161/circgenetics.114.000950
BibTeX
@article{Franken2015,
author = {Franken, Romy and den Hartog, Alexander W and Radonic, Teodora and Micha, Dimitra and Maugeri, Alessandra and van Dijk, Fleur S and Meijers-Heijboer, Hanne E and Timmermans, Janneke and Scholte, Arthur J and van den Berg, Maarten P and Groenink, Maarten and Mulder, Barbara J M and Zwinderman, Aeilko H and de Waard, Vivian and Pals, Gerard},
title = {Beneficial Outcome of Losartan Therapy Depends on Type of FBN1 Mutation in Marfan Syndrome},
journal = {Circulation: Cardiovascular Genetics},
year = {2015},
volume = {8},
number = {2},
pages = {383--388},
doi = {10.1161/circgenetics.114.000950}
}
EUVIMED